TrialSignal transduction and targeted therapy2024

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

Hua-Qiang Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.